Downloaded from ijdld.tums.ac.ir at 19:13 IRDT on Friday May 4th 2018

Transcription

1 - : -. : - 3 *. () - : : (LDL-C) (HDL-C) TG/HDL-)HDL-C TG (TC/HDL-C)HDL-C (HRs) TC (non- HDL-C) (TG) (TC) HDL. 8/4. HR. ( 98 9). TG/HDL-C (C 89 : HDL-C.[/3 (/0 -/57)] TC/HDL-C. ( C ) WHO non-hdl- HR TC/HDL-C non-hdl-c LDL-C TC. C /30 /0 HR. : LDL-C TC. TC/HDL-C C - : : - : - : : tohidi@endocrine.ac.ir 88//9 : 88//8 : 88/9/0:

2 : /5 /7.[0-]. ) 030 ([3]. C. [4]. (TLGS) TLGS TLGS ) 3 (380.[5 9] 30 ( ) ( 6) ( ) 0. ( 8/4 )387 -Discrimination power (CHD) Haffner.[ ] (MI).[3] MI MI CHD : 3 (TG) [4] 4 (HDL-C) 6 5.[5] (LDL-C) 7 (VLDL) 8.non-HDL-C (IDL) B 9 () -.[7 6] LDL-C Health professional s Follow- up 0 HDL-C (TC).[7].[8] (TLGS).[9] -Coronary heart disease (CHD) -Myocardial infarction (MI) 3-Triglycerides (TG) 4-High density lipoprotein- cholesterol (HDL-C) 5-Low density lipoprotein- cholesterol (LDL-C) 6-Altered composition 7-Very low density lipoprotein (VLDL) 8-Intermediate density lipoprotein (IDL) 9-Cardiovascular disease () 0-Cholesterol (TC) -Tehran lipid & glucose study (TLGS)

3 C. HDL TG. B. ( ) Vital Sceintific, Spankeren, The ) - TG. (Netherlands [6 ] LDL - C mg/dl 400 HDL -C non-hdl-c. TC/HDL-C TG/HDL - C. TC. HDL-C TC TG %/ HDL-C TC. TG. % 0/5.[5 9] % /6 0/6 - -.[7]... - (ECG) ] MI ECG ) MI [ [8] ( ECG ) ( ECG (m ) (kg) (BMI).. (cm) (cm) (WHR) TLGS.. 3 (OGTT) TC. -Body Mass Index (BMI) -Waist to Hip Ratio (WHR) 3-Oral Glucose Tolerance Test (OGTT)

4 : ). (387. ] 6 (SBP) FPG WHR 7 (DBP) [ P- 0/ value p stepwise backward multivariate Cox regression. 0/ SBP FPG. SBP FPG WHR WHR. SBP FPG. 8 (HRs). SD %95 9 Cox. 0. Criteria. Akaike Information (AIC).[] AIC [4] C 0/5 ) CHD ( 4. (FPG) 6 (mg/dl) [9] 00 mg/dl ":. " ( ) (WHO).[0] 4 (SD) ±. TG/HDL-C TG FPG. ( ) t Systolic blood pressure (SBP) 7-Diastolic blood pressure (DBP) 8-Hazard ratio (HR) 9-The proportional hazard assumption) 0-Schoenfild residual test -Goodness of fit -Fasting plasma glucose (FPG) -Milligram per deciliter (mg/dl) 3-World Health Organization (WHO) 4-Standard deviation(sd) 5-Cox Proportional Hazard Model

5 -. 9 SBP FPG ). ( %45 6 SD -. non-hdl- LDL-C TC SD TG/HDL-C TC/HDL-C C. - SD P=0/06] %9 HDL-C. - [0/8 (0/65-/0) TC/HDL-C [/3 (/0-/57) P=0/00] non- LDL-C SD P=0.00]. %8 HDL-C non-hdl-c LDL-C. α= 0/05 SD /30 /0. %74 %30. HDL-C SD [0/84 (0/7-/00) P =0/05 ] %6 HR. TC/HDL-C non-hdl-c LDL-C TC -C HR =/0).(LDL-C /30 TC/HDL ".( C P >0/) C %95 STATA C. Somersd.[] Jackknife (0 ) STATA. 0/05 P ( 53/4 56/6 ) 89 8/4.. - ( 98 9). non- LDL-C TC FPG DBP SBP WHR TC/HDL-C HDL-C WHR. TC/HDL -C non-hdl-c TG LDL-C TC FPG SBP. TG/HDL-C SD. TC TC/HDL-C TG LDL-C.

6 : non-hdl-c LDL-C TC TC/HDL-C TG <00 mg/dl TG 00mg/dL. 00 mg/dl TG TG.(4 ) TG P ) (Interaction).( 0/05 57±8 3/6 4/ /3 4/5 4/8 66/3 9/7±4/5 0/93±0/08 43/7±4/6 85/6±/9 6(5-7) 59/5±5/6 68/4±43/0 4(35-49) 7(70-307) 7/±5/ 5/(3/8-8/4) 6/5±/3 AIC. LDL-C LDL- TC/HDL-C non-hdl-c LDL-C. C TC/HDL-C. HDL-C non-hdl-c Non-. LDL-C AIC AIC TC/HDL -C HDL-C. TC LDL-C - - 5±0 3/ 5/7 6/9 0/6 /3 45/ 9/7±5/3 0/90±0/07 3/7±/8 83/0±0/3 30(07-77) 38/5±49/ 50/±39/ 4(35-49) 99(45-78) 94/3±48/4 4/6(3/-7/) 5/7±/7 59±0 5/4 46/ 8/4 8/9 5/ /0±3/5 0/99±0/06 43/±7/4 85/6±5/ 46(-05) 38/0±5/8 5/3±4/9 35(3-4) 33(53-308) 99/0±49/9 6/(4/3-9/3) 6/7±/ 55± /5 43/8 6/4 5/0 8/ /3±3/9 0/96±0/07 9/3±9/7 80/5±0/9 97(0-7) 7/5±4/7 34/7±35/ 35(3-4) 0(44-93) 79/7±4/6 5/5(3/8-8/9) 6/±/ ( ) (kg/m ) (mmhg) (mmhg) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) / /. 0/05 P...( 9) 43 ( 98) : ±. ) /. - t. (.

7 AIC ( %95) C 0/70(0/65-0/75) 0/70(0/65-0/76) 0/68(0/6-0/73) 0/70(0/65-0/75) 0/68(0/63-0/74) 0/69(0/64-0/74) 0/68(0/6-0/73) 0/73(0/68-0/77) 0/73(0/68-0/78) 0/73(0/68-0/77) 0/73(0/69-0/78) 0/7(0/67-0/77) 0/74(0/70-0/79) 0/7(0/68-0/77) /39(/5-/70) /45(/6-/83) 0/9(0/7-/6) /36(/4-/63) /0(/0-/43) /6(/0-/33) /06(0/9-/3) /3(0/93-/37) /8(0/97-/44) 0/8(0/66-/0) /8(0/98-/4) /0(0/84-/3) /3(/0-/57) /3(0/95-/34) /46(/-/75) /47(/8-/83) 0/90(0/7-/) /45(/0-/74) /(/03-/44) /8(/04-/34) /09(0/94-/6) /3(/-/57) /33(/-/59) 0/8(0/65-/0) /37(/6-/6) /09(0/94-/6) /44(/4-/68) /(/05-/40) / / / /. 0/05 P.... ( SBP) ( FPG) SBP FPG (WHR) Akaike Information Criteria (AIC). - C. AIC.. 0/5-3 AIC ( %95) C 366 0/73(0/70-0/76) /5(0/09-/43) /40(/3-/59) 979 0/73(0/70-0/77) /30(/-/50) /40(/-/6) 346 0/7(0/68-0/75) 0/86(0/7-/0) 0/84(0/7-/00) 338 0/73(0/70-0/76) /6(/0-/44) /4(/4-/59) 374 0/7(0/68-0/75) /(0/98-/6) /5(/03-/8) 338 0/73(0/70-0/76) /0(/0-/3) /3(/4-/34) / 347 0/7(0/68-0/75) /08(0/98-/9) /08(0/98-/9 /. 0/05 P.... Criteria (AIC) Akaike Information. 0/5 C. AIC.

8 : mg/dl 00-4 mg/dl00 > mg/dl00 /40(/04-/89) /3(/03-/45 /39(/07-/8) /30(/07-/57) /46(/09-/97) /4(/04-/47) /74(/9-/55) /8(/05-/33) /. 0/05 P... LDL-C TC.[4 3] LDL- C TC LDL-C AIC. CHD %4 TC SD.[5] (3-63% : %95 ). (3-59%) %40 LDL-C TC TC TG.[6]. LDL- C %0/7 ) LDL-C ( 400mg/dl TG.[7] TC non- HDL-C.[8 7 6] ) LDL-C TC.[9] TC/HDL-C ( Health Professional s follow-up Study. TC/HDL-C TG non- HDL-C LDL-C TC. ( C ) LDL-C ( AIC ) TC TC/HDL-C non- HDL -C TG. TG %9 HDL-C SD ).( TC/HDL-C. LDL-C non- TC/HDL-C. HDL-C TC/HDL-C non- HDL-C LDL-C TC.(%73 C ) -Asia Pacific Cohort Studies Collaboration -Multivariate adjusted sex pooled analysis

9 -. 96 TG. AIC Strong Health Professionals, Follow-up Study TG Heart.[7 6] - non- LDL-C TC TLGS TC/HDL-C HDL-C -.[7] TG HDL-C TC. 3 TG.[3] HDL-C TG TG TG ApoB Apo A-. Ingelsson. CHD ApoB/apoA.[3] TC/HDL-C ( HbAC). [33] 30 non-hdl- LDL-C C TC/HDL-C.[7] HR Strong Heart (tertile) non- HDL-C HR. TG LDL-C TC/HDL-C.[6] non-hdl-c TC/HDL-C non-hdl-c LDL-C. AIC TC/HDL-C non-hdl-c TC/HDL-C C UKPDS.[30] non-hdl-c TG Strong Heart.[7 6] TC/HDL-C.[6] TG TG HDL-C Nurses, Health. TG HDL-C 0 Schulze.[8] HDL-C TG HbAC.[8] %0 TG SD [ HR /0 (/0-/43) P =0/04] 3-Rregression dilution -Nested models -U.K Prospective Diabetes Study (UKPDS)

10 : HDL-C LDL-C TG TC.[34] WHO TC TC/HDL-C non- HDL-C LDL-C.... Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 998; 97: Gu K, Cowie CC, Harris MI: Mortality in adults with and without diabetes in a national cohort of the U.S. population, Diabetes Care 998; : Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 998; 339: Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K: Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 993; 36: OGTT..[5]. Ingelsson (C ).[3] TC) (non- HDL-C TC/HDL/C TC WHO.[3] 5. Barrett-Connor E, Grundy SM, Holdbrook MJ: Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 98; 5: Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ: Non-HDL cholesterol as a predictor of cardiovascular disease in type diabetes: the strong heart study. Diabetes Care 003; 6: Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB: Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type diabetes. Diabetes Care 004; 7: Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB et al: LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol 000; 0: Azizi F, Rahmani M, Emami H, Madjid M: Tehran Lipid and Glucose Study: rationale and design. Prevention 000; 3:4-47.

11 Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F: High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. BMC Public Health 008; 8:76.. Hadaegh F, Khalili D, Fahimfar N, Tohidi M, Eskandari F, Azizi F: Glucose intolerance and risk of cardiovascular disease in Iranian men and women: results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS). J Endocrinol Invest Harati H, Hadaegh F, Saadat N, Azizi F: Population-based incidence of Type diabetes and its associated risk factors: results from a six-year cohort study in Iran. BMC Public Health 009; 9: Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the developing world--a growing challenge. N Engl J Med 007; 356: Pencina MJ, D Agostino RB: Overall C as a measure of discrimination in survival analysis:model specific population value and confidence interval estimation. Statist Med 004; 3: Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M: Prevention of noncommunicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials 009; 0:5. 6. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 97; 8: Hadaegh F, Harati H, Ghanbarian A, Azizi F: Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil 006; 3: Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D et al: Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 003; 08: Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 003; 6: NIH Consensus and State-of-the-Science Statements. 005, Volume, Number.. Agresti A: Building and Applying Logistic Regression Models: AN introduction to categorical Data Analysis.th ed. John Wiley &Sons, Inc, Hoboken, New Jersey Roger N: Parameters behind "nonparametric" statistic: Kendall's tau, Somers'D and median differences. STATA J 00; : Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 979; 90: Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 3). BMJ 998; 36: Asia Pacific Cohort Studies Collaboration. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia 007; 50: Anderson KM, Wilson PW, Odell PM, Kannel WB: An updated coronary risk profile. A statement for health professionals. Circulation 99, 83: Homma Y: Predictors of atherosclerosis. J Atheroscler Thromb 004; : Schulze MB, Shai I, Manson JE, Li T, Rifai N: Joint role of non-hdl cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type diabetes. Diabetologia 004; 47: Wang CY, Chang TC: Non-HDL cholesterol level is reliable to be an early predictor for vascular inflammation in type diabetes mellitus. J Clin Endocrinol Metab 004; 89: Holman RR, Coleman RL, Shine BS, Stevens RJ: Non-HDL cholesterol is less informative than the total-to-hdl cholesterol ratio in predicting cardiovascular risk in type diabetes. Diabetes Care 005; 8: Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 004; 0: Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ et al: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 007; 98: American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 009; :S WHO -Risk Management Package for low- and medium-resource settings. /management/ package/en/. Geneva: World Health Organization; 00.